Drug intelligence / Profile preview

OV825

Development stage: Preclinical
Lead developer: Ovid Therapeutics
Modality: Gene Therapies

Overview

OV825 is a preclinical genetic medicine candidate developed by Ovid Therapeutics in collaboration with Columbia University. This candidate emerged from a three-year research partnership focused on genetic medicines. Ovid Therapeutics is exploring out-licensing opportunities for OV825 and other genetic programs developed through this collaboration, as the company shifts its focus to small molecule programs.

Beyond the preview

Go deeper on OV825.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OV825.

Explore the full profile